Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Abstract Text:

Michael G Haddock,Revathi Swaminathan,Nathan R Foster,Mark D Hauge,James A Martenson,John K Camoriano,Philip J Stella,Richard C Tenglin,Paul L Schaefer,Dennis F Moore,Steven R Alberts,

PURPOSE: A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Forty-eight patients with locally advanced pancreatic adenocarcinoma received gemcitabine (30 mg/m2) and cisplatin (10 mg/m2) twice weekly during the first 3 weeks of radiotherapy. The radiation dose to the primary tumor and regional nodes was 45 Gy in 25 fractions, and the gross tumor volume received an additional 5.4 Gy in three fractions. Four weeks after radiotherapy, patients received gemcitabine (1,000 mg/m2) once weekly every 3 of 4 weeks for a 12-week period. The primary end point was survival at 12 months. Secondary end points were time to progression, toxicity, and quality of life. RESULTS: Survival at 1 year was 40% for 47 eligible patients. The median survival was 10.2 months. Confirmed responses were observed for 8.5% (two partial, two complete), and median time to progression was 7.3 months. Grade 4 or higher toxicity was observed for 31% and consisted primarily of hematologic and GI toxicity. There was a trend toward improved overall quality of life, measured by the Symptom Distress Scale (P = .06), with significant improvements in domains of insomnia, pain, and outlook. CONCLUSION: The combination of radiotherapy, gemcitabine, and cisplatin was well tolerated. Survival results were similar to those achieved with other treatment regimens for patients with locally advanced pancreatic cancer but did not meet our predefined criteria for additional evaluation of this regimen.

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Publishing Authors By Initials

MG Haddock,R Swaminathan,NR Foster,MD Hauge,JA Martenson,JK Camoriano,PJ Stella,RC Tenglin,PL Schaefer,DF Moore,SR Alberts,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of clinical oncology : official journal of

VOLUME: 25

Page Numbers: 2567-72

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 20

MONTH: Jun

YEAR: 2007

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: radiotherapy

Chemical & Substance for Abstract: Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Information

Substance Name: Deoxycytidine

Registry Number: 951-77-9

Grant and Affiliation Information for Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

AFFILIATION: Mayo Clinic, Rochester, MN 55905, USA. haddock.michael@mayo.edu

Country: United States

AGENCY: United States NCI

GRANT: CA-63848

ACRONYM: CA

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942 Related Publications

• Age-related changes in grasping force modulation.
• Assay-assisted treatment selection for women with breast or ovarian cancer.
• Behavioural inbreeding avoidance in wild African elephants.
• Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway.
• Direct percutaneous intratumoral bleomycin injection for palliative treatment of impending quadriplegia.
• Effect of sodium sulfamerazine on Salmonella pullorum.
• Effects of combined robotic therapy and repetitive-task practice on upper-extremity function in a patient with chronic stroke.
• Effects of labor contractions on catecholamine release and breathing frequency in newborn rats.
• Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
• Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
• Huddling by rat pups: ontogeny of individual and group behavior.
• Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast cancer.
• Maternal anesthesia via isoflurane or ether differentially affects pre-and postnatal behavior in rat offspring.
• Mediastinal lymphadenopathy and Mycoplasma pneumoniae: an atypical presentation?
• Mesh migration following obturator hernia repair presenting as a bezoar inducing small intestinal obstruction.
• Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1.
• Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
• Paternal effects on offspring fitness in a multimale primate society.
• Pulmonary manifestations of the Churg-Strauss syndrome and related idiopathic small vessel vasculitis syndromes.
• Rat behavioral thermoregulation integrates with nonshivering thermogenesis during postnatal development.
• Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses.
• RhoB and the mammalian Diaphanous-related formin mDia2 in endosome trafficking.
• Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression.
• Skin cancer chemoprevention: strategies to save our skin.
• T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice.
• The implications of an incidental chronic lymphocytic leukaemia in a resection specimen for colorectal adenocarcinoma.
• The stroke belt consortium.
• Therapeutic Advances in GI Malignancies--Fifth Annual Conference. 13-14 July 2007, Newport Beach, CA, USA.
• Tissue plasminogen activator in acute stroke.
• Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.